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Abstract
Background: The human malaria parasite Plasmodium falciparum exploits antigenic diversity and
within-host antigenic variation to evade the host's immune system. Of particular importance are
the highly polymorphic var genes that encode the family of cell surface antigens PfEMP1 (Plasmodium
falciparum Erythrocyte Membrane Protein 1). It has recently been shown that in spite of their
extreme diversity, however, these genes fall into distinct groups according to chromosomal
location or sequence similarity, and that recombination may be confined within these groups.
Methods: This study presents a mathematical analysis of how recombination hierarchies affect
diversity, and, by using simple stochastic simulations, investigates how intra- and inter-genic
diversity influence the rate at which individuals acquire clinical immunity.
Results: The analysis demonstrates that the partitioning of the var gene repertoire has a limiting
effect on the total diversity attainable through recombination and that the limiting effect is strongly
influenced by the respective sizes of each of the partitions. Furthermore, by associating expression
of one of the groups with severe malaria it is demonstrated how a small number of infections can
be sufficient to protect against disease despite a seemingly limitless number of possible non-
identical repertoires.
Conclusion: Recombination hierarchies within the var gene repertoire of P. falciparum have a
severe effect on strain diversity and the process of acquiring immunity against clinical malaria.
Future studies will show how the existence of these recombining groups can offer an evolutionary
advantage in spite of their restriction on diversity.
Background
Although the acquisition of immunity to malaria is poorly
understood, it appears to rely on repeated exposure to dif-
ferent antigenic variants of the malaria parasite Plasmo-
dium falciparum (for a review see [1,2]). Adults living in an
endemic region will, therefore, have been exposed to, and
generated antibodies to, most of the variants circulating in
the parasite population [3-6] (although this is also
dependent on transmission intensity, see for example
[7,8]). In spite of this gradual accumulation of immunity
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tected against the most severe forms of the disease after
only a few episodes [9].
One of the main targets of protective immune responses
against P. falciparum are the highly polymorphic variant
surface antigens (VSA) [3,10-13], such as the Plasmodium
falciparum Erythrocyte Surface Proteins, PfEMP1. These
proteins are important virulence factors as they mediate
cytoadherence to a variety of host cells receptors and cause
sequestration of infected erythrocytes in vital organs such
as the brain or placenta, which is a key element in the
pathology of malaria [14-17]. PfEMP1 is encoded by a
family of about 50–60 highly variable var genes per
genome and is mutually exclusively expressed on the sur-
face of infected red blood cells in a process known as
clonal antigenic variation [18-21]. On a population level,
the enormous sequence diversity of var genes facilitates
the sequential reinfection of hosts, with the antigenic pro-
file of newly infecting parasites appearing to correspond
to a 'hole' in the antibody repertoire of the host [22-24].
Thus, immune responses elicited by one infection may
not provide protection against a pathogen with a different
set of var genes or a similar pathogen expressing a differ-
ent subset of it var gene repertoire [11].
The extensive sequence diversity of PfEMP1 observed in
the field is predominantly a consequence of high allelic
and ectopic recombination rates [25-28]. However, the
sequencing of the 3D7 malaria lab strain revealed genetic
structuring in which var genes can be grouped according
to their 5' upstream sequence (Ups) and chromosomal
location [29], dividing them into into three major groups
(A, B and C) and two intermediate groups (B/A and B/C)
[30-32]. Bull et al. [22] proposed a different grouping
based on features of short sequence tags within the Duffy-
binding-like (DBL) a domain which can be sampled from
most var genes using universal primers [28]. Even though
this grouping is based on only a small portion of the gene
it corresponds well with the ones based on whole genome
sequences and it has become apparent that recombina-
tion is, at least to some extent, confined within these
groups. Through the comparison of different P. falciparum
isolates from diverse geographical regions, for example,
Kraemer et al. [32] illustrated that these groups may be
evolving independently of each other. Furthermore, it
appears that these groups may have clinical significance,
possibly due to functional differences. Several studies
have found that severe disease in young children associ-
ates with the expression of var group A and B/A [33-35].
Rosetting is another well-known virulence factor and
recent studies have identified associations between the
rosetting phenotypes and the expression of particular
groups of var genes [22,36,37]. These studies suggest that
a relatively confined group of genes are responsible for
most of the clinical infections cause by P. falciparum; this
may also explain why immunity to clinical malaria is
acquired early on in life (depending on transmission
intensity) and after only a few episodes [9].
Understanding the implications for restricted recombina-
tion between groups of var genes is key for a proper assess-
ment of PfEMP1 as a vaccine candidate [2,38]. For
example, if there exists a small genetically isolated parti-
tion that can be associated with severe disease, this subset
would be a good vaccine candidate in much the same way
that var2CSA, whose expression has been associated with
the phenomenon of pregnancy associated malaria
[39,40], is being used as the basis for developing a preg-
nancy associated malaria vaccine (see [41] for a review of
the progress). However, not much is known about the
direct consequences of a recombination hierarchy on the
acquisition of immunity and the diversity of the global var
gene population. This question is being explored here by
first demonstrating that any partitioning of the antigenic
repertoire into genetically isolated groups has a limiting
effect on the total diversity that can be created through
recombination, and then by analysing how diversity
affects an individual's development of immunity to clini-
cal malarial disease.
Methods and Results
In the following, an antigenic type or strain of P. falci-
parum is defined by its full repertoire of var genes. Two
strains will then be said to have an overlapping repertoire
if they have one or more var genes in common. In accord-
ance with a recent model of antigenic variation in malaria,
it is assumed that each PfEMP1 contains a unique major,
immunogenic epitope [42]. The epitope itself might be
encoded by a single combination of polymorphic build-
ing blocks within the gene such that each new combina-
tion, as a result of ectopic recombination between two
genes, generates a novel epitope. For reason of simplicity,
it is assumed that the population is at equilibrium with
regards to these epitopes and every possible combination
is currently in circulation within the parasite population.
Although this assumption leads to an overestimation of
diversity, it allows us to carry out the following analysis in
disregard of ectopic recombination and generation of new
variants. Therefore, recombination is considered only
between two P. falciparum strains when it results in the
generation of novel strains that differ in their antigenic
repertoire from their 'parent' strains; this concept is illus-
trated in Figure 1.
Diversity is considered at two separate levels: intra-genic
and inter-genic. The degree of intra-genic diversity,
defined as n, refers to the number of unique epitopes at
the genome level, whereas inter-genic diversity, defined as
N, refers to the number of epitopes at the populationPage 2 of 11
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unique epitope, 'gene' and 'epitope' are interchangeable
in this context.
Diversity reduction through segmentation
Each P. falciparum genome contains around 60 var genes,
i.e. 60 unique epitopes. The extent of diversity at the pop-
ulation level, however, is much higher. As a result, allelic
recombination between distinct P. falciparum strains can
lead to an enormous number of different combinations of
genes. As a numerical example, with 800 distinct epitopes
within a local setting the number of possible non-identi-
cal repertoires that can be created through recombination
without constraints, referred to as DT, is given as
As a consequence of dividing the antigenic repertoire into
recombining groups, epitopes are only available to the
groups they are associated with. If the repertoire is divided
into two partitions or recombining groups, such that n1 +
n2 = n and N1 + N2 = N, the number of possible strains is
given by
However, the pool size of possible strains that can be cre-
ated from genomes in which recombination is partitioned
is always smaller than the pool size that can be created
from the same number of epitopes in a non-partitioned
system, that is,
Therefore, recombination hierarchies have a limiting
effect on the level of strain diversity. More importantly,
the finer the partitioning the greater is the limiting effect.
As an example, assuming that the repertoire is equally
divided into five recombining groups such that each
group has the same number of epitopes, both within the
genome and within the population, i.e. ni = n/5 = 12 and
Ni = N/5 = 160. The reduction in diversity with this group-
ing can be calculated by the ratio DP/DT (i.e. the number
of combinations with partitioning divided by the number
of combinations without partitioning):
This means that the potential pool size would be reduced
by nearly four orders of magnitude by such a partitioning.
Note that the existence of recombining blocks also
restricts the number of possible epitopes that can be cre-
ated through ectopic recombination (because the availa-
bility of 'building blocks' is limited); this puts a further
limitation on the number of possible strains. Therefore,
the diversity reduction ratio serves only as a lower bound
for the constraining effect of recombination hierarchies.
Intra- and inter-genic diversity
Allocating genes or epitopes to distinct recombining
groups limits the total number of strains but the group
size distribution itself determines the extent to which
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Homologous recombination between two strainsFigure 1
Homologous recombination between two strains. Recombination between two strains (strain 1, blue, and strain 2, red), 
shown as two cross-over events, is considered to be confined within recombining groups (here group1 and group2). Each box 
represents a particular gene. In this process, two strains emerge (strain 3 and strain 4) that differ in their antigenic repertoire 
from their parent strains.
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of 800 epitopes, with 60 epitopes per genome, is divided
into two equally sized recombining groups, the reduction
in diversity is nearly twice as much as if one group was 10
times bigger than the other group. (Naturally, in the
extreme case effectively equals an unconstrained system
which has the highest level of diversity.) Therefore, the
number of strains that can be created in a partitioned sys-
tem is greater if the partitions are unequal in size; this
holds true for any number of partitions.
What about the relationship between the intra and inter-
genic group sizes? Bull et al. [22] reported similar fre-
quency distributions of groups of var sequence tags within
the parasite genome and within the whole population
despite the fact that the groups themselves vary consider-
ably in size. That is, the relative ratios of intra to inter-
genic group sizes, ni/Ni, are equal across the groups.
Assuming a population pool of N epitopes, with each par-
asitic genome containing n epitopes grouped into two
major groups, n1 and n2, one can calculate the diversity
reduction DP/DT for varying intra to inter-genic group size
ratios, n1/N1 and n2/N2. Figure 2 shows how the diversity
reduction ratio DP/DT changes with inter-genic group size
N1 for three different values of n1 for a system N = 800 and
n = 60 (n2 and N2 are determined by n2 = n - n1 and N2 = N
- N1). In all three cases, DP/DT assumes a maximum
exactly when n1/N1 = n2/N2. For example, in the case
where n1 = 10 and n2 = 50, the smallest reduction in strain
diversity is found when N1 = 133 and N2 = N - N1 = 800 -
133 = 667, i.e. when n1/N1 = n2/N2 = 1/5. This clearly dem-
onstrates that the number of possible strains the parasite
can create through recombination is least restricted (great-
est value of DP/DT) when the frequency distributions of
Diversity reductionFigu e 2
Diversity reduction. The diversity reduction ratio DP/DT crucially depends on the relationship between the respective intra 
to inter-genic diversity ratios ni/Ni, and is minimised exactly when n1/N1 = n2/N2. A small DP/DT ratio indicates a greater reduc-
tion in diversity. n = const = 60 and N = const = 800 (n1 + n2 = n and N1 + N2 = N).
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and across the whole population. Due to symmetry, the
same results can be obtained for any number of partitions.
Overlapping repertoires
Immunity against severe malaria develops rapidly after
relatively few clinical episodes, and recent studies have
shown that severe disease may correlate with the expres-
sion of particular groups of var genes. Here it is assumed
that each genome contains between six and 10 genes of
this "severe disease" group and it is further assumed that
each gene will be expressed during the course of infection.
In the following, nSD and NSD define the number of severe
disease (SD) associated genes within the genome and
within the population, respectively. With an arbitrary
intra to inter-genic diversity ratio nSD/NSD = 1/20, a pool
of 120–200 SD-epitopes can be found within the popula-
tion, and the boundaries for the total number of unique
SD repertoires are given as
¿From now on, only epitopes associated with severe dis-
ease are being considered which allows the omission of
the subscripts, i.e. nSD = n and NSD = N. Although the
number of possible combinations of epitopes is huge, a
large proportion of these have one or more epitopes in
common. The proportion of combinations, i.e. strains,
that share i epitopes can be expressed as
and find the proportion of strains that overlap in their
repertoire of severe disease associated genes by at least one
as ∑i si, which can also be expressed as
where the last term denotes the proportion of types with
no overlap. For the lower and upper bound systems, (N,
n) = (120, 6) and (200, 10), the proportion of overlapping
types is 27% and 41%, respectively. Therefore, under the
assumption of equal intra to inter-genic diversity ratios,
larger groups tend to produce more overlapping combina-
tions as the probability of two types having epitopes in
common increases with the size of the genomic repertoire.
The assumption that every gene will be expressed during
infection is of course artificial, but serves to illustrate the
counterintuitive concept that overlap between strains
actually increases with diversity when the intra to inter-
genic diversity ratio is approximately equal. This will be
shown to have consequences for the rate at which individ-
uals acquire immunity through a series of infections.
Acquired immunity against severe disease
For an individual host suffering a series of infections, et
defines the number of SD epitopes he/she has been
exposed to after the tth infection. Recall that each type con-
tains n epitopes and so the probability of getting infected
with m novel epitopes at the next infection, is equal to the
proportion of strains that contain exactly n - m epitopes
the host has previously been exposed to (note, it is
assumed that all n genes will be expressed during the
infection). That is,
Moreover, P(e1 = n) = 1, as the first infection necessarily
results in n novel epitopes. Figure 3 illustrates the result of
a stochastic simulation of individual infection histories
where the outcome of each infection is determined by (8).
Figure 3(a) and 3(b) show the build-up of immunity in
terms of exposed epitopes with infection history for the
two systems (N, n) = (120, 6) and (200, 10). From these
plots one can notice two phenomena: first, defining ht : =
1 - et/N as the proportion of epitopes an individual has
not yet experienced after the tth infection, i.e. the gap in its
immune repertoire, then ht decays exponentially with t
(shown as insets in Figure 3(a) and 3(b)). Second, the rate
at which ht decays is equal for both systems (N, n) = (120,
6) and (200, 10). Therefore, the rate at which individuals
get exposed to novel epitopes is mostly dependent on the
ratio between the number of epitopes one experiences at
each infection and the total number of epitopes within
the population, n/N.
Here, it is assumed that the risk of developing severe dis-
ease corresponds to the probability of getting infected
with an strain that does not contain any SD associated
epitopes the host has previously been exposed to.
Although a crude assumption, it is easy to see how the
results obtained here can be applied to cases where mini-
mal overlap can also cause severe disease or even to the
case when not all genes are being expressed during infec-
tion. In terms of an individual's infection history the risk
of severe disease is then given as the probability of experi-
encing n novel epitopes at the (t + 1)th infection. That is,
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shown how the risk of severe disease decreases with each
infection t; Figure 3(c) and 3(d) show the result of the sto-
chastic simulations. In line with the gap in the host's
immune repertoire, ht, the risk of severe disease PSD decays
exponentially with infection history, and it is worth men-
tioning that even after a limited number of infections the
risk of getting infected by an entirely novel strain is mini-
mal. For example, with 200 SD associated genes in the
community and 10 per genome, the risk of severe disease
is one in 1,000 after 13 infections only. However, it takes
more than 22 infections if there are 120 SD genes in the
community and six per genome, despite the fact that the
total number of possible combinations in this case is less
by over six orders of magnitude.
In contrast to the acquisition of an immune repertoire
(through exposure to novel epitopes), the change in risk
of severe disease with infection history is strongly and sep-
arately dependent both on the intra and inter-genic diver-
sity levels. Figure 4 shows how PSD depends on the genetic
diversity of these epitopes in the population, N, keeping
the intra to inter-genic diversity ratio, n/N, constant. A sur-
prising effect of maintaining a constant n/N ratio is that
enhanced diversity leads to a sharper drop in the risk of
severe disease with every infection. For example, with 12
such genes per genome and 240 within the population, 11
infections can be sufficient to bring the risk of contracting
a discordant type down to less than one in 1,000. On the
other hand, with only six SD associated genes per genome
and a total of 120 in the population it takes twice as many
infections to gain the same level of protection.
This phenomenon occurs because larger groups tend to
produce more overlapping combinations (under the
assumption that the ratio between the number of epitopes
per genome and the total number of epitopes in the pop-
ulation is constant). Furthermore, hosts experience a
Simulation of infection historiesFig re 3
Simulation of infection histories. Stochastic simulation of five individual infection histories showing (A) the acquisition of 
immunity in terms of exposed upsA associated epitopes and (B) the drop in the risk of severe disease with the number of infec-
tions; the black lines are the averages of 100 simulations. Left panel: (N, n) = (120, 6), right panel: (N, n) = (200, 10). The insets 
show how the gap in the immune repertoire, ht, decreases with consecutive infections.
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result, after relatively few infections, the overall number of
exposed epitopes is bigger than for smaller groups (again,
under the assumption that all genes are being expressed).
Because of the extensive overlap of strains in the popula-
tion, the risk of getting infected by a novel combination
decays more rapidly. Note, these results rest on the
assumption that all epitopes are expressed during infec-
tion, although there is little data on var gene expression
patterns in vivo. From Figure 4 it is clear, however, that the
rate at which clinical protection is acquired strongly corre-
lates with the number of genes that the host experiences
per infection. If for example only a subset of genes is being
expressed during infection or reaches a sufficient level to
trigger an immune response, this would have a negative
effect on the acquisition of immunity.
Recombination and immune selection
So far it has been assumed that all possible combinations
of var genes occur within the parasite population at equal
prevalence. Another theoretical extreme can be found
within a totally structured population. Mathematical
models have shown that strong immune selection can
cause antigenically diverse pathogen populations to segre-
gate into sets of strains that are marked by discordant anti-
genic repertoires [43,44]. Within this framework,
assuming strong selection pressure and an entirely dis-
cordant pathogen population, an estimate for the lower
bound for the total diversity of strains is η : = N/n, i.e. the
total number of unique var epitopes is divided into dis-
crete, non-overlapping types. This hypothetical extreme of
a completely strain structured population means that each
infection is with a strain that is either novel or overlaps
entirely with the ones the host has previously been
Risk of severe diseaseF gure 4
Risk of severe disease. Risk of severe disease at different levels of diversity N, with n/N = const = 0.05. As the level of inter-
genic diversity increases the incremental risk of contracting a discordant strain decreases significantly. Each line represents the 
average of 100 simulations. The inset shows how the total number of strains (log scale) that can be generated through recom-
bination increases with N.
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ply given as
where e is the number of strains the host has experienced.
However, a pathogen population that is structured into
discordant types may actually lower the rate at which indi-
viduals build up protection against severe disease. Figure
5 shows how the risk of disease decreases with infection
history under the assumption of total strain structure
compared to that of a homogenous setting where all pos-
sible combinations are equally prevalent in the popula-
tion. These two extremes define the boundaries of a region
where the actual drop in the risk of severe disease can be
expected. This intermediate region is very likely to be
influence by the local settings, especially the rate and
mode of transmission.
Discussion and Conclusion
Despite different approaches to classifying the var genes of
P. falciparum, it appears that recombination between
genes and gene segments is, at least to some extent, con-
fined within a number of groups. It has been speculated
that this partitioning has evolved to accommodate various
sets of genes with distinct antigenic and adhesive charac-
teristics within each parasite genome [31,32]. Here it has
been shown that confining recombination to specific
groups also has a limiting effect on the overall level of
diversity that can be attained by the parasite.
Within the model framework, an equal ratio of intra- to
inter-genic diversity allows the parasite to generate a max-
P
e
SD =
−h
h
, (10)
Strain structured vs. homogenous populationFigure 5
Strain structured vs. homogenous population. Comparison between the decline in risk of severe disease in a homoge-
nous distribution of all possible types and a strain structured population. Both hypothetical extremes, homogenous distribution 
and complete strain structure, define the boundaries of a region (grey) within which the risk will realistically decay with expo-
sure. N = 120, n = 6, η = 20.
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such a recombination hierarchy. In fact, the limiting effect
of repertoire partitioning is strongly dependent on the
number of partitions, their respective sizes and the distri-
bution of epitopes among them. Interestingly, the lowest
pathogen population diversity will be attained if the par-
titions are exactly equal in size, whereas pathogen popu-
lations with asymmetric group sizes are able to maintain
a higher level of diversity. This prediction is consistent
with studies showing wide variations among group sizes,
although the sizes themselves seem remarkably stable.
That maximum diversity is obtained when intra- to inter-
genic diversity ratios are equal is particularly interesting in
light of findings that the groups defined by [22] do seem
to show very similar frequency distribution among the
group members within a single parasite and the popula-
tion as a whole, despite the fact that the relationship
between the genomic group size and the total pool of
genes associated with the group is non-linear. That is, the
ratio between the number of genes associated with a par-
ticular group within the genome and the number of those
genes within the population is approximately the same
for every group. One of the main caveats in the analysis is
the restriction to homologous recombination alone, how-
ever. Ectopic recombination is known to be a major gen-
erator of var gene diversity. It can be expected that the rate
at which novel and functional genes are being created and
introduced into the population is slower than homolo-
gous recombination. Therefore, the analysis can be seen as
being applied to a snapshot of the current diversity within
the population. The assumption that all possible combi-
nation exist within the population, however, might com-
pensate for disregarding the generation of novel variants.
The exact level of diversity within a population is not
known, and it is also not known if diversity is constant,
fluctuating or growing, or how fast the turnover of var
genes is. These are important considerations for future
work.
The practical implication of categorizing var genes is to
find associations between certain disease symptoms and
the expression of particular groups of genes. Several stud-
ies have already found correlations between specific
groups and clinical manifestations, such as severe child-
hood disease or rosetting, although more research is
required to establish the exact nature of these associa-
tions. For the purpose of this analysis it was assumed that
each genome contained a certain number of disease asso-
ciated genes and that clinical protection is the result of
having been exposed to a majority of circulating variants.
More precisely, the risk of severe disease was assumed to
correlate with the probability of getting infected by a
strain with a completely discordant set of these genes. This
was done for practical reasons only, although it is conceiv-
able that any pre-existing immunity, in terms of specific
antibodies, is likely to offer some degree of protection.
Furthermore, the process of acquired immunity is multi-
factorial and depends on more than the exposure to
PfEMP1. Host factors and other parasitic proteins, such as
the vaccine candidate merozoite surface protein (MSP),
might also be crucial during this process ([45-47]). The
diversity of these proteins is far more limited than
PfEMP1, however, such that within the model presented
here, a much steeper reduction in the probability of devel-
oping clinically disease with each infection can be
expected. The analytical framework presented here can
easily be extended to include different levels of diversity to
account for more than one target of protective immune
responses. However, if both targets are equally strongly
associated with protective immunity, then the least
diverse target would dominate the rate at which protec-
tion is acquired.
In terms of the actual number of genes an individual is
being exposed to during infection it was found that a
larger group size, i.e. a larger number of genes per genome
and a proportionally larger number of genes across the
population, resulted in a more significant decrease in the
risk of severe disease with each infection. This occurred for
two reasons: (i) larger groups tended to produce a higher
proportion of strains that overlap in the antigenic reper-
toire; this lowered the per-infection risk of encountering a
completely novel strain. (ii) larger groups led to hosts
being exposed to higher number of variants per infection,
which resulted in a further decrease in risk. The analysis
presented here is based on the crucial assumption that
every gene will be expressed during infection. This, how-
ever, is biologically questionable. As a result, the gradient
shown for the decline in the risk of severe disease is prob-
ably steeper than if only a certain portion of the repertoire
is being expressed. Nevertheless, the model serves to illus-
trate how the reduction in risk of severe disease can fall
rapidly in spite of vast pathogen diversity. Variant expres-
sion itself appears to be influenced by the immune status
of the host [22]. Although no specific order has been
established at which the variants are being expressed dur-
ing infection, there is some evidence that antibodies
against particular groups of genes (groups A and B/A) are
acquired earlier in life, which hints towards a predomi-
nance of this particular group [8]. This apparent predom-
inance might also help to explain why protection against
the most severe form of malaria is acquired early on in
life.
The gradient in the decline in risk of severe disease is also
influenced by the parasite population structure. Theoreti-
cal models have suggested that immune selection can seg-
regate P. falciparum into discrete strains with minimal
overlap in their antigenic repertoire [43,44]. This has been
supported by field studies that also found little or no over-Page 9 of 11
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[48,49]. These studies are not entirely conclusive as they
relied on a relatively small number of isolates or came
from regions of low-moderate transmission intensity. The
latter is expected to have a major influence on population
structure as allelic recombination is hugely favoured when
transmission is intense. Nevertheless, as Figure 5 clearly
shows, population structures can have a huge impact on
the rate at which individuals acquire protective immunity.
Both hypothetical extremes, a strain structured popula-
tion and one where all possible combinations co-circu-
late, can be seen as setting an upper and lower level for the
rate at which the risk of severe disease decreases with
infection history. The realistic rate can then be expected to
be somewhere between those boundaries, determined by
the intensity of transmission, for example.
The evolutionary forces that determine the size of each var
gene group are not clear but one can envisage a complex
and multi-factorial interplay of trade-offs between dis-
ease, infection length and host adaptation (including
both immune evasion and cytoadhesion). For example,
high levels of parasitaemia correlate with transmissibility
but also with the risk of host death. Increasing the number
of disease-associated genes might, therefore, be detrimen-
tal for the pathogen's fitness. On the other hand, retaining
a certain number of these genes may confer an evolution-
ary advantage over parasites that carry only genes associ-
ated with mild disease because of increased
transmissibility. This is highly speculative but the fact that
clinical symptoms so far have only been found to corre-
late with the expression of a relatively small set of genes
within the repertoire seems to support these claims.
Ongoing studies will help to clarify how selection pres-
sure has shaped and partitioned the var gene repertoire of
P. falciparum and how it impacts on the expression of dif-
ferent subsets of genes. This knowledge is key to under-
standing host-pathogen interaction which might aid the
design of new and ongoing intervention strategies.
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